These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The vesamicol receptor ligand (+)-meta-[125I]iodobenzyltrozamicol [(+)-[125I]-MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson's disease. Efange SM; Langason RB; Khare AB; Low WC Life Sci; 1996; 58(16):1367-74. PubMed ID: 8614294 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and tissue distribution of (m-[125I]iodobenzyl)trozamicol ([125I]MIBT): potential radioligand for mapping central cholinergic innervation. Efange SM; Michelson RH; Khare AB; Thomas JR J Med Chem; 1993 Jun; 36(12):1754-60. PubMed ID: 8510103 [TBL] [Abstract][Full Text] [Related]
4. Measurement of functional cholinergic innervation in rat heart with a novel vesamicol receptor ligand. Coffeen PR; Efange SM; Haidet GC; McKnite S; Langason RB; Khare AB; Pennington J; Lurie KG Nucl Med Biol; 1996 Oct; 23(7):923-6. PubMed ID: 8971861 [TBL] [Abstract][Full Text] [Related]
5. Striatal D2/acetylcholine interactions: PET studies of the vesamicol receptor. Ingvar M; Stone-Elander S; Rogers GA; Johansson B; Eriksson L; Parsons SM; Widén L Neuroreport; 1993 Sep; 4(12):1311-4. PubMed ID: 8260611 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the vesamicol analogue (+)-[(125)I]MIBT in primate brain. Staley JK; Mash DC; Parsons SM; Khare AB; Efange SM Eur J Pharmacol; 1997 Nov; 338(2):159-69. PubMed ID: 9455998 [TBL] [Abstract][Full Text] [Related]
7. Vesicular acetylcholine transporter density and Alzheimer's disease. Efange SM; Garland EM; Staley JK; Khare AB; Mash DC Neurobiol Aging; 1997; 18(4):407-13. PubMed ID: 9330972 [TBL] [Abstract][Full Text] [Related]
8. Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. Jung YW; Frey KA; Mulholland GK; del Rosario R; Sherman PS; Raffel DM; Van Dort ME; Kuhl DE; Gildersleeve DL; Wieland DM J Med Chem; 1996 Aug; 39(17):3331-42. PubMed ID: 8765517 [TBL] [Abstract][Full Text] [Related]
9. Comparative tissue distribution of conformationally restricted radioiodinated vesamicol receptor ligands. Efange SM; Khare AB; Langason RB Nucl Med Biol; 1995 May; 22(4):437-44. PubMed ID: 7550019 [TBL] [Abstract][Full Text] [Related]
10. Effects of a novel vesamicol receptor ligand, m-(iodobenzyl)trozamicol, on the canine isolated, blood-perfused atrioventricular node preparation. Sugiyama A; Lurie KG; Efange SMN ; Takahara A; Takehana S; Haghimoto K Jpn J Pharmacol; 2000 Feb; 82(2):150-4. PubMed ID: 10877534 [TBL] [Abstract][Full Text] [Related]
15. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390. Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879 [TBL] [Abstract][Full Text] [Related]
16. Positron-emitting N-[18F]fluoroalkyl and [18F]fluoropyrrolidinyl analogues of eticlopride as potential in vivo radioligands for dopamine D2 receptors. Maeda M; Sasaki S; Fukumura T; Fukuzawa E; Watanabe K; Kojima M; Tahara T; Masuda K; Ichiya Y Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1793-8. PubMed ID: 1394695 [TBL] [Abstract][Full Text] [Related]
17. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. Janowsky A; Neve KA; Kinzie JM; Taylor B; de Paulis T; Belknap JK J Pharmacol Exp Ther; 1992 Jun; 261(3):1282-90. PubMed ID: 1534844 [TBL] [Abstract][Full Text] [Related]
18. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673 [TBL] [Abstract][Full Text] [Related]
19. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181 [TBL] [Abstract][Full Text] [Related]
20. Piperazine analog of vesamicol: in vitro and in vivo characterization for vesicular acetylcholine transporter. Bando K; Naganuma T; Taguchi K; Ginoza Y; Tanaka Y; Koike K; Takatoku K Synapse; 2000 Oct; 38(1):27-37. PubMed ID: 10941138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]